Pfizer Partner BioNTech Sees No Role For Its Vaccine In UK Challenge Trial

In a paper https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf?ua=1 published in May, the WHO said challenge trials could be risky even if limited to young, healthy adults because too little is known about how COVID-19 progresses and there are no specific treatments apart from Gilead’s remdesivir.

U.S.-based advocacy group 1Day Sooner, which is lining up volunteers and is lobbying for challenge trials, in a media briefing on Thursday said it did not have confirmation about which vaccines had been eyed for testing in Britain.

Leading vaccine makers have each recruited tens of thousands of volunteers in late-stage trials that rely on accidental infections to yield results on efficacy.

(Additional reporting by Trisha Roy and Sri Kalyani Manojna Maddipatla; editing by Thomas Seythal and Alexandra Hudson)

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor